Collegium Pharmaceutical vs Corcept Therapeutics
Collegium Pharmaceutical and Corcept Therapeutics are similar in size: $781m and $761m of revenue in their latest fiscal years. Collegium Pharmaceutical grew faster (23.6% against 12.8%). Corcept Therapeutics kept more of each dollar of sales as profit: a net margin of 13.1% against 8.1%. Corcept Therapeutics carries less debt relative to equity (0.0% against 79.0%).
| Latest fiscal year | Collegium PharmaceuticalCOLL, 2025 | Corcept TherapeuticsCORT, 2025 |
|---|---|---|
| Revenue | $781m | $761m |
| Revenue growth | 23.6% | 12.8% |
| Net income | $62.9m | $99.7m |
| Operating margin | 23.0% | 5.9% |
| Net margin | 8.1% | 13.1% |
| Return on equity | 23.7% | 15.0% |
| Free cash flow | $328m | $142m |
| Cash | $231m | $120m |
| Total debt | $238m | $0 |
| Debt to equity | 79.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $25.1m | $173m |
| Employees | 423 | 730 |
| Market value | $769m | $8.82bn |
| Price vs our value range | Below our value range | Above our value range |
| Moat score | 48 (Moderate) | 75 (Strong) |
| Insider trades, 12 months | 0 buys, 14 sales | 2 buys, 111 sales |